Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gevokizumab in Active Non-infectious Uveitis (EYEGUARD-A)
NCT01684345Phase 3Terminated
- Sponsor
- XOMA
- Start
- Aug 2012
- Primary completion
- Feb 2016
- Modality
- Monoclonal Antibodies
- Countries
- 22
01
Overview
A Phase 3 trial of gevokizumab in non-infectious intermediate uveitis, Posterior uveitis (non-infectious), non-infectious panuveitis (NIU), sponsored by XOMA. Started Aug 2012; status: terminated.
02
Drugs
gevokizumab
03
Conditions
non-infectious intermediate uveitisPosterior uveitis (non-infectious)non-infectious panuveitis (NIU)
Beyond the preview
Go deeper on NCT01684345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01684345.